A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 4, 2015

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.

DRUG

GDC-0810

GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.

Trial Locations (44)

2010

St Vincent's Hospital Sydney, Darlinghurst

2444

Port Macquarie Base Hospital, Port Macquarie

3011

Footscray Hospital, Footscray

3121

Epworth HealthCare; Clinical Trials Centre, Richmond

3199

Peninsula and South Eastern Haematology and Oncology Group, Frankston

5037

Adelaide Cancer Centre, Kurralta Park

7000

Royal Hobart Hospital; Medical Oncology, Hobart

10408

National Cancer Center, Goyang-si

15006

Complejo Hospitalario Universitario A Coruña; Servicio de Endocrinologia, A Coruña

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

25198

Hospital Universitari Arnau de Vilanova, Lleida

28007

Hospital General Universitario Gregorio Marañon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

28040

Hosp. Clinico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

33705

Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), St. Petersburg

33908

Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers

37067

Tennessee Oncology PLLC, Franklin

41404

Kyungpook National University Medical Center, Daegu

44033

Ulsan University Hosiptal, Ulsan

45242

Oncology Hematology Care Inc, Cincinnati

46010

Hospital Clinico Universitario de Valencia, Valencia

47805

HELIOS Klinikum Krefeld; Klinik für Frauenheilkunde und Geburtshilfe, Krefeld

56068

Praxisklinik für Hämatologie und Onkologie Dres. Köppler/Heymans/Weide/Thomalla, Koblenz

58452

Marien Hospital Witten Gemeinnützige GmbH, Witten

72076

Universitätsklinikum Tübingen, Tübingen

76104

The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth

77030

MD Anderson Cancer Center, Houston

80637

Rotkreuzklinikum München; Frauenklinik, München

06520

Yale Cancer Center, New Haven

01307

"Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden", Dresden

(0)6351

Samsung Medical Center, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

08308

Korea University Guro Hospital, Seoul

08036

Hospital Clinic, Barcelona

08003

Hospital del Mar, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

BN2 5BE

Royal Sussex County Hospital, Brighton

EH4 2XU

Western General Hospital, Edinburgh

EC1A 7BE

St Bartholomew's Hospital, London

N7 9NH

University College Hospital, London

W1G 6AD

Sarah Cannon Research Institute, London

SK10 3BL

Macclesfield District General Hospital, Macclesfield

NG5 1PB

Nottingham City Hospital, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY